E.L. (Eline) Hooijman

Eline Hooijman is a researcher and PhD candidate at the Radiopharmacy group, which is a joint research group between the department of Radiology & Nuclear Medicine and the department of Hospital Pharmacy.

Her research is centred in the field of clinical implementation of unregistered radiopharmaceuticals, focusing on Quality Control, Radionuclide Therapy and Targeted Alpha Therapy (TAT) for the treatment of metastatic disease.

She has worked on KWF (Dutch Cancer Foundation) funded projects for the clinical development of the radiopharmaceuticals and [225Ac]Ac-PSMA-I&T for the treatment of metastatic Castration Resistant Prostate Cancer (mCRPC) and [225Ac]Ac-DOTA-TATE for the treatment of neuroendocrine tumours. Her research contributed to the start of a phase I 3+3 dose-escalation study into the safety and efficacy of these treatments. 

• Radiopharmaceutical Implementation
• Quality Control of Radiopharmaceuticals
• Targeted Alpha Therapy (TAT)

Eline received her BSc in Biopharmaceutical Sciences (2015) from the University of Leiden (NL). Thereby, also following Nuclear Medicine courses at Uppsala University (SE). She started a Master’s Degree in Clinical Research at the Netherlands Institute for Health Sciences (NIHES), with a successful defence of her thesis; “Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy (TAT) According to GMP Guidelines for Treatment of metastatic Castration Resistant Prostate Cancer (mCRPC)”. Eline continued her research within a PhD-project at the Radiopharmacy group, in close collaboration with Dr. Erik de Blois, Dr. Stijn Koolen (co-promotors), Prof. Dr. F.A. Verburg and Prof. Dr. P.H.M. van der Kuy (promotors).

• Supervision of MSc and MLO students

• NKRV travel grant (2022)